Ketamine Therapy Among Patients With Treatment-resistant Depression: A Randomised, Double-blind, Placebo-controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,069,382.00
Summary
In the last decade, there have been reports of powerful antidepressant effects after a single injection of anaesthetic ketamine, with dramatic (though shortlasting) effects within 24 hours. This will be the first controlled study to test whether a course of repeated ketamine treatments, given over 4 weeks, is effective and safe in treating depression.
ASPREE-D; Aspirin In The Prevention Of Depression In The Elderly
Funder
National Health and Medical Research Council
Funding Amount
$796,784.00
Summary
The ASPREE (ASPirin in Reducing Events in the Elderly) study is a 5 year RCT of aspirin (100mg daily) or placebo in 19,000 healthy people over 70. We aim to augment the existing infrastructure of ASPREE in order to confirm the utility of aspirin for the prevention of depression in the elderly (ASPREE-D). The primary aim of ASPREE-D is to determine if use of low-dose aspirin reduces the incidence of de-novo episodes of depression in healthy individuals over 70 years of age.
Antipsychotic Medication In First-episode Psychosis: An RCT To Assess The Risk-benefit Ratio
Funder
National Health and Medical Research Council
Funding Amount
$1,141,117.00
Summary
There has been an increasing emphasis on intervening early in psychotic disorders. A fundamental principle in early intervention is “to do no harm” and benefits must outweigh the risks of treatment. While antipsychotic medication is very effective and evidence-based form of treatment for positive symptoms in most first episode psychosis (FEP) patients it has risks. This study has the potential to determine whether antipsychotic medication should be the initial treatment option for FEP.
Prevention Of Asthma In Young Children Via Immunostimulation
Funder
National Health and Medical Research Council
Funding Amount
$679,683.00
Summary
Persistent asthma is a major problem for Australia yet none of the current therapies do more that control the condition. The long-term solution is to prevent asthma from progressing to the persistent form. The major risk factors are: family history, early allergy and recurrent severe lower respiratory infections (sLRI) in the early life. We will conduct a randomized clinical trial to prevent sLRI using a novel bacterial-derived immunostimulant in infants at high risk of developing asthma.
Footwear For Self-managing Knee Osteoarthritis Symptoms: The Footstep Trial
Funder
National Health and Medical Research Council
Funding Amount
$590,532.00
Summary
Self-management of symptoms is an important part of treatment for people with knee osteoarthritis. Footwear influences forces across the knee joint and it is unclear which types of shoes are best to minimise arthritis symptoms. This study will compare the effects of flat flexible shoes to stable supportive shoe styles on pain and physical function over 6 months in people with painful knee osteoarthritis.
Reducing The Greatest Uncertainty In Radiotherapy.
Funder
National Health and Medical Research Council
Funding Amount
$594,197.00
Summary
The weakest link in radiotherapy is defining treatment volumes (contouring). Lack of accuracy and consistency in clinical trial contouring has been shown to result in reduced patient outcomes. Manual review of contouring is resource intensive, expensive and for advanced treatments unachievable in a timely fashion. We will assess an automated approach to contouring assessment using 4 clinical trial datasets, changing practice for future studies and enabling consistent assessment in the clinic.
Periodontal Disease And Chronic Kidney Disease Among Aboriginal Adults; An RCT
Funder
National Health and Medical Research Council
Funding Amount
$1,035,550.00
Summary
Chronic Kidney Disease is a growing public health concern in Australia, especially among Aboriginal populations. It is associated with progression to end stage kidney disease requiring dialysis, cardiovascular disease burden and high mortality. This study will use a randomised controlled trial design to determine if comprehensive periodontal therapy reduces progression of kidney disease among Aboriginal adults with chronic kidney disease residing in Central Australia.
Treatment Of Invasively Ventilated Adults With Early Activity And Mobilisation
Funder
National Health and Medical Research Council
Funding Amount
$1,467,137.00
Summary
The sickest patients in intensive care units (ICUs) receive prolonged, invasive support for their breathing. This is currently managed with complete bed rest, and results in severe muscle weakness, increased duration of hospital stay and poor recovery. We have found that early activity and mobilisation during invasive breathing support is safe and may improve survival and recovery. We will test early activity and mobilisation in a large randomised controlled trial of 750 ICU patients.
The N-ICE Trial: A Randomised Controlled Trial Of The Safety And Efficacy Of N-Acetyl Cysteine (NAC) As A Pharmacotherapy For Methamphetamine (“ice”) Dependence
Funder
National Health and Medical Research Council
Funding Amount
$1,551,368.00
Summary
Crystalline methamphetamine (aka ‘ice’) is a significant public health concern in Australia and globally. Currently there are no approved medications to treat methamphetamine dependence. We will trial tN-acetyl-cysteine (NAC) as a medications for methamphetamine dependence.
A Randomised Trial Of A Clinical Prediction Tool For Targeting Depression Care (Target-D)
Funder
National Health and Medical Research Council
Funding Amount
$944,774.00
Summary
The Target-D Study uses a novel clinical prediction tool to test a new approach to depression care in general practice based upon sub-grouping patients into low, medium and high risk of ongoing depression. Participants will be randomly allocated to targeted treatments based upon their risk profile or to usual general practice care. We will measure whether the new approach results in greater improvements in depressive symptoms, quality of life and functioning and whether there are cost benefits.